C. Kanthou

发表

Expression of vascular endothelial growth factor receptors in smooth muscle cells

A. Ishida, Jacqueline Murray, Yuji Saito, 2001, Journal of cellular physiology.

An automatic segmentation algorithm for the morphological analysis of microvessels in immunostained histological tumour sections

C C Reyes-Aldasoro, G M Tozer, C. Kanthou, 2011 .

Long-term chemotaxis studies on adherent cells: effect of platelet-derived growth factor-BB on human vascular smooth muscle cell migration.

C. Kanthou, O. Benzakour, V. Kakkar, 1995, Analytical biochemistry.

Variability in the proliferative responsiveness of cultured human vascular smooth muscle cells to α‐thrombin

C. Kanthou, O. Benzakour, V. Kakkar, 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Disrupting tumour blood vessels

Chryso Kanthou, Gillian M. Tozer, Bruce C. Baguley, 2005, Nature Reviews Cancer.

The protective role of sphingosine-1-phosphate against the action of the vascular disrupting agent combretastatin A-4 3-O-phosphate

C. Kanthou, D. McDonald, G. Tozer, 2017, Oncotarget.

Vascular effects dominate solid tumor response to treatment with combretastatin A‐4‐phosphate

C. Kanthou, C. Reyes-Aldasoro, G. Tozer, 2011, International journal of cancer.

The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro.

C. Kanthou, B. Vojnovic, G. Tozer, 2003, Anticancer research.

Rational Design of Cholesterol Derivative for Improved Stability of Paclitaxel Cationic Liposomes

C. Kanthou, G. Tozer, P. Vavia, 2018, Pharmaceutical Research.

Evidence for a protein S receptor(s) on human vascular smooth muscle cells. Analysis of the binding characteristics and mitogenic properties of protein S on human vascular smooth muscle cells.

D. Cooper, C. Kanthou, O. Benzakour, 1995, The Biochemical journal.

The vitamin K-dependent anticoagulant factor, protein S, inhibits multiple VEGF-A-induced angiogenesis events in a Mer- and SHP2-dependent manner.

C. Kanthou, O. Benzakour, S. Kanse, 2012, Blood.

Tumour Cells Expressing Single VEGF Isoforms Display Distinct Growth, Survival and Migration Characteristics

C. Kanthou, C. Reyes-Aldasoro, W. English, 2014, PloS one.

human endothelial cells reorganization of the actin cytoskeleton and early membrane blebbing in The tumor vascular targeting agent combretastatin A-4-phosphate induces

C. Kanthou, G. Tozer, 2007 .

Horseradish peroxidase-mediated gene therapy: choice of prodrugs in oxic and anoxic tumor conditions.

C. Kanthou, G. Tozer, L. Folkes, 2001, Molecular cancer therapeutics.

The in(cid:426)uence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin

Andrew W. Brown, C. Kanthou, T. Holmes, 2020 .

The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death.

Chryso Kanthou, C. Kanthou, O. Benzakour, 2004, The American journal of pathology.

Targeting the endoplasmic reticulum mediates radiation sensitivity in colorectal cancer.

C. Kanthou, T. Drake, L. Wyld, 2015, Experimental and molecular pathology.

Acute intraoperative heparin-induced thrombocytopenia (HIT) and thrombosis during coronary artery bypass grafting: Two case reports providing evidence for the role of preoperative LMWH in triggering sensitization.

C. Kanthou, G. Soufla, A. Pitsis, 2016, Thrombosis research.

Prothrombin cleavage by human vascular smooth muscle cells: A potential alternative pathway to the coagulation cascade

D. Cooper, C. Kanthou, O. Benzakour, 1995, Journal of cellular biochemistry.

Thrombin‐induced proliferation and expression of platelet‐derived growth factor‐A chain gene in human vascular smooth muscle cells

C. Kanthou, E. Wijelath, V. Kakkar, 1992, FEBS letters.

Debunking the Myth of the Endogenous Antiangiogenic Vegfaxxxb Transcripts

C. Kanthou, W. English, D. Simpson, 2020, Trends in Endocrinology & Metabolism.

The proliferative responsiveness of human vascular smooth muscle cells to endothelin correlates with endothelin receptor density.

C. Kanthou, E. Wijelath, V. Kakkar, 1995, Laboratory investigation; a journal of technical methods and pathology.

Use of Low Molecular Weight Heparin in Pregnancy

K. Nicolaides, C. Kanthou, V. Kakkar, 1992, Thrombosis and Haemostasis.

Perioperative use of iloprost in cardiac surgery patients diagnosed with heparin‐induced thrombocytopenia‐reactive antibodies or with true HIT (HIT‐reactive antibodies plus thrombocytopenia): An 11‐year experience

C. Kanthou, G. Soufla, A. Karabinis, 2015, American journal of hematology.

Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders.

K. Preissner, C. Kanthou, O. Benzakour, 1997, Arteriosclerosis, thrombosis, and vascular biology.

Cellular effects and signalling pathways activated by the anti-coagulant factor, protein S, in vascular cells protein S cellular effects.

C. Kanthou, O. Benzakour, 2000, Advances in experimental medicine and biology.

The biology of the combretastatins as tumour vascular targeting agents

C. Kanthou, G. Tozer, S. Hill, 2002, International journal of experimental pathology.

Sydnone Cycloaddition Route to Pyrazole-Based Analogs of Combretastatin A4.

Andrew W. Brown, C. Kanthou, G. Tozer, 2016, Journal of medicinal chemistry.

Differential Expression of VEGFA Isoforms Regulates Metastasis and Response to Anti-VEGFA Therapy in Sarcoma.

C. Kanthou, S. Lyons, W. English, 2017, Cancer research.

Do Anti-Angiogenic VEGF (VEGFxxxb) Isoforms Exist? A Cautionary Tale

C. Kanthou, D. Shima, G. Tozer, 2012, PloS one.

Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors.

Christiana Ruhrberg, Chryso Kanthou, Constantino C Reyes-Aldasoro, 2008, Cancer research.

Evaluation of Sydnone‐Based Analogues of Combretastatin A‐4 Phosphate (CA4P) as Vascular Disrupting Agents for Use in Cancer Therapy

Andrew W. Brown, C. Kanthou, G. Tozer, 2018, ChemMedChem.

Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies

Chryso Kanthou, C. Kanthou, G. Tozer, 2009, International journal of experimental pathology.

The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells.

C. Kanthou, G. Tozer, 2002, Blood.

Limitations of the reporter green fluorescent protein under simulated tumor conditions.

C. Kanthou, G. Tozer, M. Čemažar, 2001, Cancer research.

The endothelial cytoskeleton as a target of electroporation-based therapies

C. Kanthou, G. Tozer, M. Čemažar, 2006, Molecular Cancer Therapeutics.

Radiation effects on the cytoskeleton of endothelial cells and endothelial monolayer permeability.

Chryso Kanthou, Gaurang C. Patel, Kevin M Prise, 2007, International journal of radiation oncology, biology, physics.

'Circulatory Disease Risk', report of the independent Advisory Group on Ionising Radiation

Bryn A. Bridges, Jolyon H Hendry, Ioanna Tzoulaki, 2010 .

Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth

C. Kanthou, Jennifer E. Podesta, G. Tozer, 2010, Proceedings of the National Academy of Sciences.

Targeting the vasculature of tumours: combining VEGF pathway inhibitors with radiotherapy.

C. Kanthou, G. Tozer, 2018, The British journal of radiology.

An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate

C. Kanthou, C. Reyes-Aldasoro, G. Tozer, 2014, British journal of pharmacology.

Tumour vascular disrupting agents: combating treatment resistance.

G M Tozer, C. Kanthou, B. Vojnovic, 2008, The British journal of radiology.

Vascular Disrupting Agents in Cancer Therapy

C. Kanthou, G. Tozer, D. Chaplin, 2008 .

Selective destruction of the tumour vasculature by targeting the endothelial cytoskeleton

C. Kanthou, G. Tozer, 2007 .

Tumour targeting by microtubule-depolymerising vascular disrupting agents

C. Kanthou, G. Tozer, 2007, Expert opinion on therapeutic targets.

Mechanisms of cytotoxicity induced by horseradish peroxidase/indole‐3‐acetic acid gene therapy

C. Kanthou, G. Tozer, G. Dachs, 2002, Journal of cellular biochemistry.

The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphate

Andrew W. Brown, C. Kanthou, G. Tozer, 2020, Scientific Reports.

Cardiac endothelial cells isolated from mouse heart - a novel model for radiobiology.

C. Kanthou, P. Widłak, M. Pietrowska, 2011, Acta biochimica Polonica.

Thrombin activates transcription factors sp1, NF-kappaB, and CREB: importance of the use of phosphatase inhibitors during nuclear protein extraction for the assessment of transcription factor DNA-binding activities.

C. Kanthou, O. Benzakour, C. Edmead, 1999, Analytical biochemistry.

Heme Oxygenase and the Novel Tumour-Specific Anti-Vascular Compound Combretastatin A4-Phosphate

C. Kanthou, G. Tozer, R. Foresti, 2002 .

The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphate

Andrew W. Brown, C. Kanthou, G. Tozer, 2020, Scientific Reports.

The anticoagulant factor, protein S, is produced by cultured human vascular smooth muscle cells and its expression is up-regulated by thrombin.

C. Kanthou, O. Benzakour, 2000, Blood.

Thrombin Receptor Activating Peptide (TRAP) Stimulates Mitogenesis, c-fos and PDGF-A Gene Expression in Human Vascular Smooth Muscle Cells

C. Kanthou, O. Benzakour, V. Kakkar, 1995, Thrombosis and Haemostasis.

Cellular and Molecular Effects of Thrombin in the Vascular System

C. Kanthou, O. Benzakour, V. Kakkar, 1998 .

Influence of soluble or matrix‐bound isoforms of vascular endothelial growth factor‐A on tumor response to vascular‐targeted strategies

Meit A. Bjorndahl, C. Kanthou, C. Reyes-Aldasoro, 2013, International journal of cancer.

Wearable Insulin Biosensors for Diabetes Management: Advances and Challenges

C. Kanthou, S. Psoma, 2023, Biosensors.

F017 Differential effects of growth factors on gap junction expression in cultured human aortic smooth muscle cells

C. Kanthou, N. Severs, F. Lupu, 1998 .

Anti-vascular agent Combretastatin A-4-P modulates Hypoxia Inducible Factor-1 and gene expression

C. Kanthou, G. Tozer, M. Currie, 2006, BMC Cancer.

Involvement of pertussis toxin-sensitive and -insensitive G proteins in alpha-thrombin signalling on cultured human vascular smooth muscle cells.

C. Kanthou, O. Benzakour, V. Kakkar, 1996, Cellular signalling.

Evidence for Cultured Human Vascular Smooth Muscle Cell Heterogeneity: Isolation of Clonal Cells and Study of their Growth Characteristics

C. Kanthou, O. Benzakour, V. Kakkar, 1996, Thrombosis and Haemostasis.

Differential Expression of VEGFA Isoforms Regulates Metastasis and Response to Anti-VEGFA Therapy in Sarcoma.

C. Kanthou, S. Lyons, W. English, 2017, Cancer research.

Measuring cellular migration with image processing

Constantino Carlos Reyes-Aldasoro, D Biram, Chryso Kanthou, 2008 .

Evaluation of the use of the luciferase-reporter-gene system for gene-regulation studies involving cyclic AMP-elevating agents.

D. Cooper, C. Kanthou, O. Benzakour, 1995, The Biochemical journal.

The anticoagulant factor, protein S, is produced by cultured human vascular smooth muscle cells and its expression is up-regulated by thrombin.

C. Kanthou, O. Benzakour, 2000, Blood.

An automatic algorithm for the segmentation and morphological analysis of microvessels in immunostained histological tumour sections

C. Kanthou, C. Reyes-Aldasoro, S. Akerman, 2011, Journal of microscopy.

Abstract 5296: The role of VEGF receptors 1 and 2 on tumor vascularization and progression in single VEGF isoform expressing tumors

C. Kanthou, G. Tozer, S. J. Lunt, 2012 .